Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission

We studied the in vitro electrical activity of rat neostriatal neurons following chronic neuroleptic treatment. In haloperidol‐treated rats, unlike naive animals, activation of neostriatal D2 dopamine receptors induced a potent presynaptic inhibition of glutamate‐mediated excitatory synaptic potentials. Haloperidol treatment did not affect the intrinsic membrane properties of the neostriatal neurons. Pre‐ and postsynaptic physiological responses to direct and indirect gamma‐aminobutyric acid (GABA)–ergic and cholinergic agonists were not affected by chronic haloperidol treatment. These findings suggest that movement disorders induced by chronic neuroleptic treatment may result, at least in part, from a hypersensitivity of presynaptic D2 dopamine receptors regulating the release of glutamate.

[1]  T. Harmony,et al.  Na-K-ATPase distribution in the brain of the rabbit , 1967 .

[2]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[3]  Hugh J. Spencer.  Antagonism of cortical excitation of striatal neurons by glutamic acid diethyl ester: Evidence for glutamic acid as an excitatory transmitter in the rat striatum , 1976, Brain Research.

[4]  P. Mcgeer,et al.  Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.

[5]  I. Divac,et al.  High affinity uptake of glutamate in terminals of corticostriatal axons , 1977, Nature.

[6]  S. Snyder,et al.  Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum , 1978, Nature.

[7]  P. Spano,et al.  Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. , 1978, Life sciences.

[8]  M. Cuénod,et al.  Glutamate release in vitro from corticostriatal terminals , 1979, Brain Research.

[9]  P. Seeman.  Brain dopamine receptors. , 1980, Pharmacological reviews.

[10]  M. Memo,et al.  Aging process affects a single class of dopamine receptors , 1980, Brain Research.

[11]  P. Jenner,et al.  Kainic acid lesions of striatum and decortication reduce specific [3H]sulpiride binding in rats, so D‐2 receptors exist post‐synaptically on corticostriate afferents and striatal neurons , 1981, The Journal of pharmacy and pharmacology.

[12]  F. Bloom,et al.  Dopaminergic supersensitivity induced by denervation and chronic receptor blockade is additive , 1982, Nature.

[13]  S. T. Kitai,et al.  Morphological and physiological properties of neostriatal neurons: An intracellular horseradish peroxidase study in the rat , 1982, Neuroscience.

[14]  J. Lehmann,et al.  The striatal cholinergic interneuron: Synaptic target of dopaminergic terminals? , 1983, Neuroscience.

[15]  S. Fahn,et al.  Dopamine receptors in the denervated striatum: further supersensitivity by chronic haloperidol treatment , 1983, Brain Research.

[16]  L. Gunne,et al.  Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis , 1984, Nature.

[17]  M. Frotscher,et al.  Identification of projecting neurons in rat neostriatal slices , 1984, Brain Research.

[18]  M. Folstein,et al.  EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN , 1984, Science.

[19]  J. Penney,et al.  Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. , 1985, Science.

[20]  G. Wooten,et al.  Localization of D-2 dopamine receptors to intrinsic striatal neurones by quantitative autoradiography , 1986, Nature.

[21]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[22]  C. Tamminga,et al.  Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. , 1987, Archives of general psychiatry.

[23]  P. Calabresi,et al.  Intracellular studies on the dopamine-induced firing inhibition of neostriatal neurons in vitro: Evidence for D1 receptor involvement , 1987, Neuroscience.

[24]  J. Joyce,et al.  Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: Localization to intrinsic neurons and not to neocortical afferents , 1987, Neuroscience.

[25]  P. Calabresi,et al.  Intrinsic membrane properties of neostriatal neurons can account for their low level of spontaneous activity , 1987, Neuroscience.

[26]  G Maura,et al.  Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. , 1988, The Journal of pharmacology and experimental therapeutics.

[27]  P. Calabresi,et al.  Depletion of catecholamines reveals inhibitory effects of bromocryptine and lysuride on neostriatal neurones recorded intracellularly in vitro , 1988, Neuropharmacology.

[28]  C. Finch,et al.  Dopaminergic Changes in the Basal Ganglia A Generalized Phenomenon of Aging in Mammals a , 1988, Annals of the New York Academy of Sciences.

[29]  P. Calabresi,et al.  Endogenous dopamine and dopaminergic agonists modulate synaptic excitation in neostriatum: Intracellular studies from naive and catecholamine-depleted rats , 1988, Neuroscience.

[30]  J. Penney,et al.  NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.

[31]  P. Calabresi,et al.  Physiology and pharmacology of dopamine D2‐receptors , 1989, Neurology.

[32]  M. Ebadi,et al.  Dopamine, GABA, cholecystokinin and opioids in neuroleptic-induced tardive dyskinesia , 1988, Neuroscience & Biobehavioral Reviews.

[33]  P. Calabresi,et al.  Kainic acid on neostriatal neurons intracellularly recorded in vitro: electrophysiological evidence for differential neuronal sensitivity , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  P. Calabresi,et al.  Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatum , 1990, Neuroscience Letters.

[35]  S. Potkin,et al.  Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain , 1990, Synapse.

[36]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[37]  H. Akil,et al.  Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization- receptor autoradiographic analysis , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[38]  T. Yamauchi,et al.  Characterization of sulpiride-displaceable 3H-YM-09151-2 binding sites in rat frontal cortex and the effects of subchronic treatment with haloperidol on cortical D-2 dopamine receptors. , 1990, Life sciences.

[39]  Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain. , 1990, The Journal of pharmacology and experimental therapeutics.

[40]  G. Debonnel,et al.  Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[41]  G Bernardi,et al.  Involvement of GABA systems in feedback regulation of glutamate‐and GABA‐mediated synaptic potentials in rat neostriatum. , 1991, The Journal of physiology.

[42]  H. Fibiger,et al.  Chronic haloperidol administration increases the density of D2 dopamine receptors in the medial prefrontal cortex of the rat , 2004, Psychopharmacology.